| Overview |
| bsm-62959r-cy55-100ul |
| PKD2 Recombinant Monoclonal Antibody, Cy5.5 Conjugated |
| WB, FCM, IF(ICC) |
| Human, Mouse |
| Specifications |
| Cy5.5 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human PKD2 |
| Monoclonal |
| Recombinant |
| IgG |
| Lot dependent |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 25865 |
| Q9BZL6 |
| HSPC187; nPKC D2; nPKC-D2; PKD2; PRKD 2; Prkd2. |
| Serine/threonine-protein kinase that converts transient diacylglycerol (DAG) signals into prolonged physiological effects downstream of PKC, and is involved in the regulation of cell proliferation via MAPK1/3 (ERK1/2) signaling, oxidative stress-induced NF-kappa-B activation, inhibition of HDAC7 transcriptional repression, signaling downstream of T-cell antigen receptor (TCR) and cytokine production, and plays a role in Golgi membrane trafficking, angiogenesis, secretory granule release and cell adhesion. |
| Application Dilution |
| WB |
1:300-5000 |
| FCM |
1:20-100 |
| IF(ICC) |
1:50-200 |
Powered by Bioz